SRRK
Scholar Rock Holding Corp
NASDAQ · Healthcare · Biotechnology · US
$41.36
+2.78%Price chart
Sep 21Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20
Key dataOct 20, 2026
Open$40.38
From 52W high−31.11%
Volume1.61M
Market cap$5.04B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 20, 2026
Open
$40.38
From 52W high
−31.11%
Volume
1.61M
Market cap
$5.04B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−12.0x
P/E (TTM)
—
RSI (14)
37.1
MomentumView details →
1D Return
+2.78%
YTD Return
−5.44%
SummaryUpdated Jun 1, 2026
Scholar Rock Holding Corporation (NASDAQ:SRRK) is a Cambridge, Massachusetts-based biopharmaceutical company founded in 2012 that focuses on discovering and developing medicines targeting protein growth factor signaling pathways. The company went public in May 2018 and has emerged as a leader in developing highly selective inhibitors of latent growth factor activation, particularly targeting myostatin and transforming growth factor beta (TGF-β) pathways. Scholar Rock's lead drug candidate, apitegromab, recently completed successful Phase 3 clinical trials for treating spinal muscular atrophy and is currently under regulatory review by the FDA, with potential approval expected in September 2025.
Similar companies
Latest newsMore news →
Kuehn Law, PLLC announced it is investigating whether certain officers and directors of Scholar Rock Holding Corp breached their fiduciary duties to shareholders.20d agoScholar Rock set a list price of $11,659 per single-use vial for its newly approved spinal muscular atrophy drug, the first therapy directly targeting muscle loss in patients with the rare genetic disorder.36d agoThe U.S. Food and Drug Administration approved Scholar Rock's therapy for a rare genetic condition that causes muscle weakness.39d ago